Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tiziana Life Sciences: Advancing at speed
- Published:
05 Aug 2020 -
Author:
Emma Ulker -
Pages:
4
Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations